Prenetics Global (NASDAQ:PRE – Get Free Report) and Genprex (NASDAQ:GNPX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.
Valuation and Earnings
This table compares Prenetics Global and Genprex”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prenetics Global | $92.39 million | 3.50 | -$37.71 million | ($4.58) | -4.18 |
| Genprex | N/A | N/A | -$16.23 million | ($310.77) | -0.03 |
Analyst Ratings
This is a summary of recent ratings for Prenetics Global and Genprex, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 1 | 0 | 4 | 0 | 2.60 |
| Genprex | 1 | 0 | 0 | 0 | 1.00 |
Prenetics Global currently has a consensus price target of $34.25, indicating a potential upside of 78.80%. Given Prenetics Global’s stronger consensus rating and higher possible upside, analysts clearly believe Prenetics Global is more favorable than Genprex.
Institutional and Insider Ownership
25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 0.3% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Prenetics Global has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Genprex has a beta of -0.92, meaning that its share price is 192% less volatile than the S&P 500.
Profitability
This table compares Prenetics Global and Genprex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -62.45% | -20.33% | -15.42% |
| Genprex | N/A | -247.32% | -176.73% |
Summary
Prenetics Global beats Genprex on 9 of the 13 factors compared between the two stocks.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
About Genprex
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
